Responsiveness and the Minimal Clinically Important Difference for HM-PRO in Patients with Hematological Malignancies

Conclusion: This study has established the responsiveness and MCID for both Part A and Part B of HM-PRO. The HM-PRO is capable of detecting small but clinically important changes in patients' HRQoL over time. The MCID for Part A based on SEM was 6.2 and for PART B 5.9 points. It would therefore be prudent, for practical reasons, to propose a MCID of '6' for the HM-PRO.DisclosuresOliva: Sanofi: Consultancy, Speakers Bureau; La Jolla: Consultancy; Amgen: Consultancy, Speakers Bureau; Celgene: Consultancy, Other: Royalties, Speakers Bureau; Janssen: Consultancy, Speakers Bureau; Novartis: Consultancy, Speakers Bureau. Ionova: BMS: Research Funding; Takeda: Research Funding.
Source: Blood - Category: Hematology Authors: Tags: 904. Outcomes Research-Malignant Conditions: Poster I Source Type: research

Related Links:

In conclusion, 4SC-202 could induce apoptosis via the NF-κB pathway, and our present finding may provide a novel therapeutic strategy for MDS. PMID: 32655823 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
CONCLUSION: We proposed a novel molecular mechanism of imatinib resistance in CML in which the high expression of Lyn in imatinib-resistant cells inhibited Ac-Foxo1 and p53 expression through the BCR-ABL/SIRT1/Foxo1 signaling pathway, thus reducing apoptosis and mediating imatinib resistance. PMID: 32655803 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
CONCLUSION: LINC00265 attenuates AML cell apoptosis by inducing autophagy via miR-485/IRF2 axis. PMID: 32655783 [PubMed]
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
This study investigated the expressions of centromere-associated genes in MM patients, their potential as prognostic markers, and their roles in disease progression. Several cohorts of 2301 MM patients were enrolled and gene expression profiling (GEP) was used to screen for CENP-A through CENP-W. Correlations between centromere-associated genes and clinicopathological characteristics, proliferative activity and recurrence of MM patients were analyzed. Clinically, CENP-E/H/K/L/N/U/W expressions were present at high-risk MM, which were even stronger elevated in patients with high tumor burden and recurrence. Mechanistically,...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Authors: Jagadeesh R, Babu G, Lakshmanan H, Oh OM, Jang JK, Kong KW, Raaman N Abstract OBJECTIVE: The aim of the present study is to isolate and characterize the bioactive compounds responsible for cytotoxic activity against human breast cancer (MDA-MD-231) and mouse T cell lymphoma (EL4) cell lines. MATERIALS AND METHODS: Sequential fractionization and column chromatography methods were involved in the compound isolation. The structures of the isolated compound were determined by NMR, GC/MS and X-ray crystallography studies. RESULTS: The isolated compounds 1- 4 [D-mannitol (C1), Ergosta-5,7,22-trien-3&beta...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - Category: Cardiology Tags: Cardiovasc Hematol Agents Med Chem Source Type: research
Authors: Paul B, Atrash S, Bhutani M, Voorhees P, Hamadeh I, Usmani SZ Abstract INTRODUCTION: A subcutaneous formulation of daratumumab, a human immunoglobulin G1 kappa monoclonal antibody targeting CD38, recently achieved FDA approval for both newly diagnosed and relapsed refractory multiple myeloma amid promises to decrease infusion times and rates of infusion reactions in myeloma patients. AREAS COVERED: In this article the biology behind subcutaneous administration of oncologic antibody therapies is reviewed and the subcutaneous formulation of daratumumab is covered in depth. The most recent results from th...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
Conditions:   Acute Lymphoblastic Leukemia, Pediatric;   Pediatric ALL;   Pediatric Lymphoma;   Bone Loss;   Metabolic Syndrome;   Habitual Physical Activity;   Precursor Cell Lymphoblastic Leukemia;   Lymphoma;   Leukemia;   Lymphoid Leukemia;   Pediatric;   Osteoporosis;   Osteoporo sis Risk Intervention:   Sponsor:   University of Nebraska Not yet recruiting
Source: - Category: Research Source Type: clinical trials
Publication date: Available online 15 July 2020Source: Gynecologic Oncology ReportsAuthor(s): Hiroko Murata, Harumi Nakamura, Yukinobu Ohta, Masanori Kitamura, Shinichi Nakastuka, Jun Ishikawa, Shoji Kamiura
Source: Gynecologic Oncology Reports - Category: OBGYN Source Type: research
Conclusions: Our report provides a definite conceptual framework for a better understanding of the characteristics of MDS/MPN-RS-T. PMID: 32657243 [PubMed - in process]
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
This study aimed to explore the protective effects of Wenshen-Yanggan decoction on dopaminergic (DA) neuron injury in a rotenone-induced mouse model with chronic Parkinson's disease (PD) and explore its mechanism of action. Ultraperformance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was used to measure the content of six main components in the Wenshen-Yanggan decoction. The chronic PD mouse model was established by treating 10-month-old healthy wild C57BL/6 male mice with rotenone 30 mg/kg/day for 28 days in succession. The pole test and rotarod test were applied to detect the rescue effect of Wensh...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukaemia | Hematology | Hodgkin's Disease | Leukemia | Lymphoma | Myelodysplastic Syndrome | Myeloma | Myeloproliferative Disorders | Non-Hodgkin's Lymphoma | Statistics | Study